曲伏前列素对已行超声乳化人工晶状体植入术的POAG患者的眼压控制

目的：观察曲伏前列素滴眼液对已行白内障超声乳化人工晶状体植入术的原发性开角型青光眼患者的降眼压效果及安全性。

方法：采用随机、单盲、平行对照试验，选取白内障超声乳化人工晶状体植入术后的原发性开角型青光眼患者，治疗组入选43例43眼滴用曲伏前列素每日1次，对照组入选43例43眼滴用布林佐胺滴眼液早晚各1次，共观察12wk。观察的指标主要包括眼压、眼部症状以及不良反应等。

结果：治疗组眼压从(24.20±3.01)mmHg降至(16.77±2.89)mmHg； 对照组从(23.87±3.47)mmHg降至(18.81±3.07)mmHg，两组用药前后眼压相比均有显著差异(P<0.01)，各时间点两组间眼压相比存在统计学差异(P<0.05)。用药后治疗组结膜充血及眼痒明显重于对照组，但不妨碍继续用药。未发现其他眼部改变和全身副作用。

结论：曲伏前列素对控制已行白内障超声乳化人工晶状体植入术的原发性开角型青光眼的眼压是高效和安全的。

Travoprost effect on IOP in POAG patients with phacoemulsification and intraoclular lens implantaion

AIM: To investigate the effect of lowering intraocular pressure(IOP)and side effect of travoprost(TA)on phacoemulsification and intraoclular lens(IOL)implantation in primary open-angle glaucoma(POAG).

METHODS: Patients with POAG already received surgery of phacoemulsification and IOL implantation were selected by randomized, single-blind, parallel group trial. TA was applied once a day in 43 patients(43 eyes)of treatment group and brinzolamide was used twice in 43 patients(43 eyes)of control group. All patients were observed for 12wk. IOP, ocular symptom and adverse reaction etc. were observed.

RESULTS: The daily average IOP(mean±standard deviation)in the treatment group decreased from(24.20±3.01)mmHg(1mmHg=0.133kPa)to(16.77±2.89)mmHg and that in the control group was from(23.87±3.47)mmHg to(18.81±3.07)mmHg. IOP pre- and pro-treatment within two groups had significant difference(P<0.01), IOP between the groups at each time point had statistical difference(P<0.05). Conjunetival congestion increased and itching in treatment group was obviously more serious than that in the control group, but the treatment could continue. No other ocular and systemic adverse events related to the drugs were found.

CONCLUSION: It is demonstrated that travoprost is highly effective and safe in reducing IOP in POAG already received surgery of phacoemulsification and IOL implantation.